1. During an 80-week trial period of patient’s with early Parkinson’s disease (PD), there was no difference in the severity of symptoms between patients treated with levodopa-carbidopa for all 80 weeks (early-start group) versus those treated with levodopa-carbidopa for the second 40 weeks (delayed-start group).
2. There was no significant...
1. Levodopa provided a small but consistent benefit for treatment of Parkinson’s disease as compared to levodopa-sparing regimens including dopamine agonists and monoamine oxidase B inhibitors (MAOBIs).
2. Among levodopa sparing regimens, MAOBIs were at least as effective as dopamine agonists.
Evidence Rating Level: 2 (Good)
Feb 14th - Neurostimulation improved quality of life for Parkinson’s disease patients with early levodopa-induced motor complications.
1. Neurostimulation improved quality of life for Parkinson’s disease patients with early levodopa-induced motor complications.
The study showed that neurostimulation could improve quality of life when given in combination with medical therapy for...